Inhibition of AKT1/2/3 with cetuximab has been reported as a promising therapeutic strategy for acquired cetuximab resistance in HNSCC patients (Zaryouh et al., 2021). This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.